LL-37

As research shows

LL-37 is a next-generation peptide derived from the human cathelicidin family, designed to exert broad-spectrum antimicrobial and immunomodulatory effects — disrupting microbial membranes, modulating immune cell responses, and influencing inflammation pathways — three powerful mechanisms that influence pathogen defense, tissue repair, and immune balance. With its multifaceted pleiotropic action, LL-37 provides broader and more impactful host defense effects than traditional single-target antimicrobials.
This 10mg research vial is an ideal entry point for precise dosing protocols in studies exploring antimicrobial activity, wound healing, anti-biofilm effects, immune modulation, infection control, and overall innate immune enhancement. If required, can increase to higher dose.

Key benefits
• Exhibits potent broad-spectrum antimicrobial activity against bacteria (including antibiotic-resistant strains), viruses, fungi, and parasites through direct membrane disruption
• Disrupts biofilms and combats chronic or intracellular infections
• Modulates immune responses with both pro- and anti-inflammatory effects to balance inflammation and enhance host defense
• Promotes wound healing, tissue repair, angiogenesis, and re-epithelialization
• Enhances chemotaxis and activation of immune cells like neutrophils, macrophages, and dendritic cells
• Provides multi-pathway host defense support for comprehensive antimicrobial and immunomodulatory control
• Early data suggests possible anticancer effects in certain models, anti-biofilm synergy, and benefits in viral infections or sepsis